Literature DB >> 24362362

A new roadmap for drug development for Alzheimer's disease.

Robert E Becker1, Nigel H Greig2, Ezio Giacobini3, Lon S Schneider4, Luigi Ferrucci5.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24362362      PMCID： PMC4668586          DOI： 10.1038/nrd3842-c2

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  11 in total

1.  Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.

Authors:  Bruno Vellas; Maria C Carrillo; Cristina Sampaio; H Robert Brashear; Eric Siemers; Harald Hampel; Lon S Schneider; Michael Weiner; Rachelle Doody; Zaven Khachaturian; Jesse Cedarbaum; Michael Grundman; Karl Broich; Ezio Giacobini; Bruno Dubois; Reisa Sperling; Gordon K Wilcock; Nick Fox; Philip Scheltens; Jacques Touchon; Suzanne Hendrix; Sandrine Andrieu; Paul Aisen
Journal:  Alzheimers Dement       Date:  2013-07       Impact factor: 21.566

2.  Sting of Alzheimer's failures offset by upcoming prevention trials.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

3.  Down's syndrome and Alzheimer's disease: towards secondary prevention.

Authors:  Seth Ness; Michael Rafii; Paul Aisen; Michael Krams; Wayne Silverman; Husseini Manji
Journal:  Nat Rev Drug Discov       Date:  2012-09       Impact factor: 84.694

4.  Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease.

Authors:  Paul S Aisen; Bruno Vellas; Harald Hampel
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

Review 5.  Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible.

Authors:  Eric M Reiman; Jessica B S Langbaum; Pierre N Tariot
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

6.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Authors:  Peder Buchhave; Lennart Minthon; Henrik Zetterberg; Asa K Wallin; Kaj Blennow; Oskar Hansson
Journal:  Arch Gen Psychiatry       Date:  2012-01

Review 7.  Lost in translation: neuropsychiatric drug development.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Sci Transl Med       Date:  2010-12-08       Impact factor: 17.956

Review 8.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

9.  Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study.

Authors:  Kerryn E Pike; Kathryn A Ellis; Victor L Villemagne; Norm Good; Gael Chételat; David Ames; Cassandra Szoeke; Simon M Laws; Giuseppe Verdile; Ralph N Martins; Colin L Masters; Christopher C Rowe
Journal:  Neuropsychologia       Date:  2011-04-16       Impact factor: 3.139

10.  Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network.

Authors:  John C Morris; Paul S Aisen; Randall J Bateman; Tammie L S Benzinger; Nigel J Cairns; Anne M Fagan; Bernardino Ghetti; Alison M Goate; David M Holtzman; William E Klunk; Eric McDade; Daniel S Marcus; Ralph N Martins; Colin L Masters; Richard Mayeux; Angela Oliver; Kimberly Quaid; John M Ringman; Martin N Rossor; Stephen Salloway; Peter R Schofield; Natalie J Selsor; Reisa A Sperling; Michael W Weiner; Chengjie Xiong; Krista L Moulder; Virginia D Buckles
Journal:  Clin Investig (Lond)       Date:  2012-10-01
View more
  26 in total

1.  Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development.

Authors:  David Tweedie; Lital Rachmany; Dong Seok Kim; Vardit Rubovitch; Elin Lehrmann; Yongqing Zhang; Kevin G Becker; Evelyn Perez; Chaim G Pick; Nigel H Greig
Journal:  J Neurosci Methods       Date:  2016-02-08       Impact factor: 2.390

2.  PET imaging of garbage protein in Alzheimer's disease: does it require reappraisal of brain PET analysis?

Authors:  Serge Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05       Impact factor: 9.236

3.  Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond.

Authors:  Nigel H Greig; Debomoy K Lahiri
Journal:  Curr Alzheimer Res       Date:  2014-02       Impact factor: 3.498

4.  Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus.

Authors:  Ghulam M Ashraf; Nigel H Greig; Taqi A Khan; Iftekhar Hassan; Shams Tabrez; Shazi Shakil; Ishfaq A Sheikh; Syed K Zaidi; Mohammad Akram; Nasimudeen R Jabir; Chelaprom K Firoz; Aabgeena Naeem; Ibrahim M Alhazza; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

5.  Amyloid-β precursor protein synthesis inhibitors for Alzheimer's disease treatment.

Authors:  Nigel H Greig; Kumar Sambamurti; Debomoy K Lahiri; Robert E Becker
Journal:  Ann Neurol       Date:  2014-09-05       Impact factor: 10.422

6.  Thermodynamic and kinetic design principles for amyloid-aggregation inhibitors.

Authors:  Thomas C T Michaels; Andela Šarić; Georg Meisl; Gabriella T Heller; Samo Curk; Paolo Arosio; Sara Linse; Christopher M Dobson; Michele Vendruscolo; Tuomas P J Knowles
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-14       Impact factor: 11.205

Review 7.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

8.  Amyloid-beta protein clearance and degradation (ABCD) pathways and their role in Alzheimer's disease.

Authors:  Robert J Baranello; Krishna L Bharani; Vasudevaraju Padmaraju; Nipun Chopra; Debomoy K Lahiri; Nigel H Greig; Miguel A Pappolla; Kumar Sambamurti
Journal:  Curr Alzheimer Res       Date:  2015       Impact factor: 3.498

9.  1-Trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) Urea, a Selective and Potent Dual Inhibitor of Soluble Epoxide Hydrolase and p38 Kinase Intervenes in Alzheimer's Signaling in Human Nerve Cells.

Authors:  Zhibin Liang; Bei Zhang; Meng Xu; Christophe Morisseau; Sung Hee Hwang; Bruce D Hammock; Qing X Li
Journal:  ACS Chem Neurosci       Date:  2019-08-19       Impact factor: 4.418

Review 10.  Does traumatic brain injury hold the key to the Alzheimer's disease puzzle?

Authors:  Robert E Becker; Dimitrios Kapogiannis; Nigel H Greig
Journal:  Alzheimers Dement       Date:  2017-12-12       Impact factor: 21.566
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.